Eli Lilly price target raised to $1,000 from $997 at BofA

BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after “good” Q4 results and first-time FY25 EPS guidance of $22.50-$24.00 that implies a midpoint roughly in line with consensus. For 2025/2026 and the late 2020s, the firm’s total revenue and EPS forecasts increase by a low single-digit percentage, notes the analyst, who made no changes to BofA’s Mounjaro or Zepbound forecasts.